Marijuana consumers’ support for the Trump administration’s actions on cannabis has declined in the months since the Department of Justice first announced it was moving forward with rescheduling the drug, a new survey reveals.
The latest quarterly presidential approval tracking poll from NuggMD and Marijuana Moment shows that 48 percent percent of marijuana consumers now either “approve” or “strongly approve” of the Trump administration’s cannabis actions.
A total of 13 percent disapprove, and 40 percent say they have no opinion or are neutral.
The numbers represent a significant drop in cannabis’ consumers support for the Trump administration’s actions on the issue from last quarter, when favorability came in at 73 percent.
| “Do you approve or disapprove of the presidential administration’s actions on cannabis?” | ||
| n: | % | |
| Strongly approve | 76 | 15% |
| Approve | 166 | 33% |
| No opinion/Neutral | 202 | 40% |
| Disapprove | 43 | 8% |
| Strongly disapprove | 23 | 5% |
Acting Attorney General Todd Blanche in April issued an order that immediately reclassified state-licensed medical cannabis, as well as marijuana products approved by the Food and Drug Administration (FDA) from Schedule I of the Controlled Substances Act (CSA) to Schedule III. Under a separate order the acting attorney general signed, a hearing is considering more comprehensively moving marijuana to Schedule III.
Testimony in the cannabis rescheduling hearing, overseen by a Drug Enforcement Administration (DEA) judge, concluded last week, and participants are now set to file their final briefs by August 17. After that, the judge will issue his own recommendation on rescheduling, and the DEA administrator will then issue a final decision on whether or not to adopt the reform.
A separate recent NuggMD poll conducted this month found that most cannabis consumers aren’t optimistic that marijuana rescheduling will be fully implemented by the end of the year.
“Rescheduling continues to be popular among cannabis voters, but our polling shows a clear divide between support for medical rescheduling versus recreational reforms,” Tyler Elson, NuggMD’s director of content, told Marijuana Moment. “That or we’re seeing consumers declare that they don’t believe the DEA will get rescheduling done.”
“I’m not surprised that support among consumers is down from the highs we saw after medical cannabis rescheduling. There have always been cannabis voters who draw a line between medical and recreational use,” he said. “I think the White House was expecting the formal rescheduling hearing to maintain that momentum among cannabis voters. And right now that’s not what our polling is showing.”
When asked in the latest poll how their support for the administration would change if it were to more fully legalize marijuana, 54 percent of cannabis consumers said they would either support it much more (39 percent) or a bit more (15 percent), and 46 percent said their level of support would not change.
| “If the Trump administration were to more fully legalize cannabis, would that change your level of support for it?” | ||
| n: | % | |
| I would support it much more | 198 | 39% |
| I would support it a bit more | 78 | 15% |
| No change | 233 | 46% |
| I would support it a bit less | 0 | 0% |
| I would support it much less | 1 | 0% |
The new survey involved interviews with 510 cannabis consumers who live in states with legal markets from July 9-15, with a +/-4.34 percentage point margin of error.
Meanwhile, DEA, which has been charged with defending the rescheduling proposal during the hearing has focused testimony on the medical benefits of cannabis and its relative safety compared to alcohol and other substances—despite excluding reform supporters from participating in the proceedings.
The cannabis rescheduling move is also being challenged in court through a number of lawsuits from the drug testing industry, a pharmaceutical corporation, legalization opponents and others.
The results of the prior quarterly NuggMD/Marijuana Moment tracking poll represented a massive swing in support for the Trump administration’s marijuana policy actions from consumers compared to the last quarter of 2025, before the president issued an executive order directing officials to finalize rescheduling.
White House Press Secretary Karoline Leavitt said in April that the administration is moving forward with marijuana rescheduling because cannabis reform is “overwhelmingly popular” with voters and because doing so will help people who need access to the drug for medical purposes.
In May, a House committee voted to block federal officials from taking further steps to carry out cannabis rescheduling.
The post Marijuana Consumers’ Support For Trump’s Actions Drops As Most Don’t Believe Rescheduling Will Be Completed This Year, Poll Shows appeared first on Marijuana Moment.
